Share：
Share this content in WeChat
X
[Chinese][PDF]950113
• Clinical Article •
Study on the value of liver-specific contrast agent MRI abbreviated sequence in screening small hepatocellular carcinoma in high-risk population
WANG Cong  GUO Ran  SHI Dandan  YU Changjiang  ZHOU Yiran  ZHU Shaocheng 

Cite this article as: Wang C, Guo R, Shi DD, et al. Study on the value of liver-specific contrast agent MRI abbreviated sequence in screening small hepatocellular carcinoma in high-risk population[J]. Chin J Magn Reson Imaging, 2021, 12(9): 20-24. DOI:10.12015/issn.1674-8034.2021.09.005.


[Abstract] Objective To compare the screening ability of three groups of abbreviated MRI sequences for small hepatocellular carcinoma (small hepatocellular carcinoma, sHCC) in a high-risk population of hepatocellular carcinoma (HCC). Materials andMethods The images of 121 patients with pathological results who underwent full sequence gadoxetic acid-enhanced MR in Henan People's Hospital from January 2017 to October 2020 were collected. Three groups of optimized sequences were extracted from the whole sequence for independent evaluation by two radiologists: (1) Non-contrast group, including T2WI and DWI sequences. (2) Dynamic enhancement group, including four-phase enhanced images of disodium gadolinium (early arterial phase, arterial phase, portal venous phase, equilibrium phase). (3) Hepatobiliary phase group, including T2WI, DWI and 20 min T1-HBP sequences. According to the pathological results, the patients were divided into positive or negative liver cancer, and the diagnostic efficiency of the abbreviated sequence in the three groups was calculated.Results The scanning and preparation time of the three groups of abbreviated MRI sequences (minutes: seconds) are 12:52, 13:04 and 14:06, respectively. The sensitivity and 95% confidence interval of the three abbreviated sequences for diagnosing small hepatocellular carcinoma were 0.855 (0.750, 0.928), 0.913 (0.820, 0.967), 0.942 (0.858, 0.984), and the specificity was 0.731 (0.590, 0.844), 0.904 (0.790, 0.968), 0.885 (0.766,0.956). The coincidence rate was 0.802 (0.719, 0.869), 0.909 (0.843, 0.954), 0.917 (0.853, 0.960). The positive likelihood ratios of the three groups were 3.18, 9.51, 8.19, the negative likelihood ratios were 0.19, 0.09, 0.06, and the Youden index was 0.586, 0.817 and 0.827 respectively.Conclusions The sensitivity of non-contrast group is higher, which is helpful for small hepatocellular carcinoma screening, while the specificity and coincidence rate of dynamic enhancement group and hepatobiliary phase group are higher, and the diagnostic efficacy of screening small hepatocellular carcinoma is better.
[Keywords] small hepatocellular carcinoma；Gd-EOB-DTPA；abbreviated magnetic resonance imaging sequence；screening；liver；contrast agent；magnetic resonance imaging

WANG Cong1   GUO Ran2   SHI Dandan2   YU Changjiang2   ZHOU Yiran2   ZHU Shaocheng2*  

1 Henan Provincial People's Hospital of Xinxiang Medical College, Xinxiang 453003, China

2 Medical Imaging Department, Henan Provincial People's Hospital, Zhengzhou 450003, China

Zhu SC, E-mail: zsc2686@163.com

Conflicts of interest   None.

ACKNOWLEDGMENTS This article is supported by the Special Project of Key R&D and Promotion in Henan Province (Scientific and Technological Research) (No. 212102310729).
Received  2021-04-05
Accepted  2021-06-29
DOI: 10.12015/issn.1674-8034.2021.09.005
Cite this article as: Wang C, Guo R, Shi DD, et al. Study on the value of liver-specific contrast agent MRI abbreviated sequence in screening small hepatocellular carcinoma in high-risk population[J]. Chin J Magn Reson Imaging, 2021, 12(9): 20-24. DOI:10.12015/issn.1674-8034.2021.09.005.

[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in Globocan 2012[J]. Int J Cancer, 2015, 136(5): E359-386. DOI: 10.1002/ijc.29210.
[2]
Izzo F, Piccirillo M, Albino V, et al. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients[J]. HPB(Oxford), 2013, 15(12): 985-990. DOI: 10.1111/hpb.12080.
[3]
Tseng PL, Wang JH, Tung HD, et al. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening[J]. J Gastroenterol Hepatol, 2010, 25(8): 1426-1434. DOI: 10.1111/j.1440-1746.2010.06285.x.
[4]
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130(7): 417-422. DOI: 10.1007/s00432-004-0552-0.
[5]
Tzartzeva K, Obi J, Rich N, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a Meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718.e1. DOI: 10.1053/j.gastro.2018.01.064.
[6]
Milot L. Does Hepatocellular Carcinoma Screening with US Work? Using the US LI-RADS Algorithm[J]. Radiology, 2019, 292(2): 398-399. DOI: 10.1148/radiol.2019191105.
[7]
Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2011, 9(2): 161-167. DOI: 10.1016/j.cgh.2010.09.017.
[8]
Kim S, An J, Lim Y, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J]. JAMA Oncol, 2017, 3(4): 456-463. DOI: 10.1001/jamaoncol.2016.3147.
[9]
Imbriaco M, De Luca S, Coppola M, et al. Diagnostic accuracy of gd-eob-dtpa for detection hepatocellular carcinoma (HCC): a comparative study with dynamic contrast enhanced magnetic resonance imaging (MRI) and dynamic contrast enhanced computed tomography (CT)[J]. Pol J Radiol, 2017, 82: 50-57. DOI: 10.12659/PJR.899239.
[10]
Cao L, Li R, Zhang Q, et al. Progress of Gd-EOB-DTPA in the diagnosis and evaluation of HCC[J]. Chin J Magn Reson Imaging, 2020, 10(11): 943-946. DOI: 10.12015/issn.1674-8034.2020.10.028.
[11]
Rao SX, Wang J, Wang J, et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium[J]. J Dig Dis, 2019, 20(2): 54-61. DOI: 10.1111/1751-2980.12707.
[12]
Morgan TA, Maturen KE, Dahiya N, et al. US Li-Rads: ultrasound liver imaging reporting and data system for screening and surveillance of hepatocellular carcinoma[J]. Abdom Radiol (NY), 2018, 43(1): 41-55. DOI: 10.1007/s00261-017-1317-y.
[13]
Abdominal Division of Radiology Society of Chinese Medical Association. Expert consensus on clinical application of hepatobiliary- specific MRI contrast agent Gd-EOB-DTPA[J]. Chin J Radiol, 2016, 9(50): 641-646. DOI: 10.3760/cma.j.issn.1005-1201.2016.09.001.
[14]
Di Tommaso L, Spadaccini M, Donadon M, et al. Role of liver biopsy in hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(40): 6041-6052. DOI: 10.3748/wjg.v25.i40.6041.
[15]
Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid[J]. Abdom Radiol (NY), 2017, 42(1): 179-190. DOI: 10.1007/s00261-016-0841-5.
[16]
Whang S, Choi MH, Choi JI, et al. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas[J]. Eur Radiol, 2020, 30(8): 4150-4163. DOI: 10.1007/s00330-020-06754-4.
[17]
Park HJ, Jang HY, Kim SY, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound[J]. J Hepatol, 2020, 72(4): 718-724. DOI: 10.1016/j.jhep.2019.12.001.
[18]
Gupta P, Soundararajan R, Patel A, et al. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis[J]. J Hepatol, 2021, 75(1): 108-119. DOI: 10.1016/j.jhep.2021.01.041.
[19]
Tillman BG, Gorman JD, Hru JM, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening[J]. Clin Radiol, 2018, 73(5): 485-493. DOI: 10.1016/j.crad.2017.11.013.
[20]
Marks RM, Ryan A, Heba ER, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance[J]. AJR Am J Roentgenol, 2015, 204(3): 527-535. DOI: 10.2214/AJR.14.12986.
[21]
Bashir MR, Gupta RT, Davenport MS, et al. Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?[J]. J Magn Reson Imaging, 2013, 37(2): 398-406. DOI: 10.1002/jmri.23818.
[22]
Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2017, 8(6): e101. DOI: 10.1038/ctg.2017.26.

PREV Preliminary study on papillary muscle morphology of the left ventricle in patients with hypertrophic cardiomyopathy by cardiac MR imaging
NEXT Diagnostic performance of MRI and CT for hepatocellular carcinoma less than 3cm based on liver reporting and data system version 2018
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn